Diabetes and nephropathy

Research output: Contribution to journalReview article

117 Citations (Scopus)

Abstract

Purpose of review: Diabetic nephropathy is the single most common disorder leading to renal failure. Its annual incidence has more than doubled in the past decade to reach 44% of all end-stage renal disease, despite recent therapeutic advances. Thus, research into diabetic nephropathy pathophysiology that could lead to new treatment approaches is urgently needed and this review aims to summarize the work performed in this area in the past year. Recent findings: There have been advances in the understanding of diabetic nephropathy pathology. Clearly, structural changes may be advanced before any clinical findings are apparent. Not all functional consequences of the condition are explained by current structural analyses. Genetic studies have connected the disorder risk to multiple candidate genes and a few genetic loci, but the exact genetic predisposition or protectors are not fully described. Perturbations in multiple metabolic pathways are associated with diabetic nephropathy in animals and humans, but their relative importance requires further work. Glycemia and blood pressure control are crucial for diabetic nephropathy prevention and treatment, but new modalities are needed. Summary: Recent advances in molecular biology and genetics will bring new insights to the mechanisms involved in diabetic nephropathy development. This will allow early identification of patients at risk of, or safe from, diabetic nephropathy and will hopefully lead to preventive strategies, based on the understanding of the pathophysiology of the disorder. Meanwhile, aggressive implementation of proven therapies to prevent (glycemic control) and slow (antihypertensive therapy, especially with renin-angiotensin system blockers) the progression of diabetic nephropathy are strongly recommended.

Original languageEnglish (US)
Pages (from-to)273-282
Number of pages10
JournalCurrent opinion in nephrology and hypertension
Volume12
Issue number3
DOIs
StatePublished - May 1 2003

Fingerprint

Diabetic Nephropathies
Molecular Biology
Therapeutics
Genetic Loci
Genetic Predisposition to Disease
Renin-Angiotensin System
Metabolic Networks and Pathways
Antihypertensive Agents
Chronic Kidney Failure
Renal Insufficiency
Pathology
Blood Pressure
Incidence
Research
Genes

Keywords

  • Diabetic nephropathy
  • Pathology
  • Pathophysiology
  • Treatment

Cite this

Diabetes and nephropathy. / Caramori, M. Luiza; Mauer, Michael.

In: Current opinion in nephrology and hypertension, Vol. 12, No. 3, 01.05.2003, p. 273-282.

Research output: Contribution to journalReview article

@article{ca3b5dd2dfb042c8ab8b240b9d4ee683,
title = "Diabetes and nephropathy",
abstract = "Purpose of review: Diabetic nephropathy is the single most common disorder leading to renal failure. Its annual incidence has more than doubled in the past decade to reach 44{\%} of all end-stage renal disease, despite recent therapeutic advances. Thus, research into diabetic nephropathy pathophysiology that could lead to new treatment approaches is urgently needed and this review aims to summarize the work performed in this area in the past year. Recent findings: There have been advances in the understanding of diabetic nephropathy pathology. Clearly, structural changes may be advanced before any clinical findings are apparent. Not all functional consequences of the condition are explained by current structural analyses. Genetic studies have connected the disorder risk to multiple candidate genes and a few genetic loci, but the exact genetic predisposition or protectors are not fully described. Perturbations in multiple metabolic pathways are associated with diabetic nephropathy in animals and humans, but their relative importance requires further work. Glycemia and blood pressure control are crucial for diabetic nephropathy prevention and treatment, but new modalities are needed. Summary: Recent advances in molecular biology and genetics will bring new insights to the mechanisms involved in diabetic nephropathy development. This will allow early identification of patients at risk of, or safe from, diabetic nephropathy and will hopefully lead to preventive strategies, based on the understanding of the pathophysiology of the disorder. Meanwhile, aggressive implementation of proven therapies to prevent (glycemic control) and slow (antihypertensive therapy, especially with renin-angiotensin system blockers) the progression of diabetic nephropathy are strongly recommended.",
keywords = "Diabetic nephropathy, Pathology, Pathophysiology, Treatment",
author = "Caramori, {M. Luiza} and Michael Mauer",
year = "2003",
month = "5",
day = "1",
doi = "10.1097/00041552-200305000-00008",
language = "English (US)",
volume = "12",
pages = "273--282",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Diabetes and nephropathy

AU - Caramori, M. Luiza

AU - Mauer, Michael

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Purpose of review: Diabetic nephropathy is the single most common disorder leading to renal failure. Its annual incidence has more than doubled in the past decade to reach 44% of all end-stage renal disease, despite recent therapeutic advances. Thus, research into diabetic nephropathy pathophysiology that could lead to new treatment approaches is urgently needed and this review aims to summarize the work performed in this area in the past year. Recent findings: There have been advances in the understanding of diabetic nephropathy pathology. Clearly, structural changes may be advanced before any clinical findings are apparent. Not all functional consequences of the condition are explained by current structural analyses. Genetic studies have connected the disorder risk to multiple candidate genes and a few genetic loci, but the exact genetic predisposition or protectors are not fully described. Perturbations in multiple metabolic pathways are associated with diabetic nephropathy in animals and humans, but their relative importance requires further work. Glycemia and blood pressure control are crucial for diabetic nephropathy prevention and treatment, but new modalities are needed. Summary: Recent advances in molecular biology and genetics will bring new insights to the mechanisms involved in diabetic nephropathy development. This will allow early identification of patients at risk of, or safe from, diabetic nephropathy and will hopefully lead to preventive strategies, based on the understanding of the pathophysiology of the disorder. Meanwhile, aggressive implementation of proven therapies to prevent (glycemic control) and slow (antihypertensive therapy, especially with renin-angiotensin system blockers) the progression of diabetic nephropathy are strongly recommended.

AB - Purpose of review: Diabetic nephropathy is the single most common disorder leading to renal failure. Its annual incidence has more than doubled in the past decade to reach 44% of all end-stage renal disease, despite recent therapeutic advances. Thus, research into diabetic nephropathy pathophysiology that could lead to new treatment approaches is urgently needed and this review aims to summarize the work performed in this area in the past year. Recent findings: There have been advances in the understanding of diabetic nephropathy pathology. Clearly, structural changes may be advanced before any clinical findings are apparent. Not all functional consequences of the condition are explained by current structural analyses. Genetic studies have connected the disorder risk to multiple candidate genes and a few genetic loci, but the exact genetic predisposition or protectors are not fully described. Perturbations in multiple metabolic pathways are associated with diabetic nephropathy in animals and humans, but their relative importance requires further work. Glycemia and blood pressure control are crucial for diabetic nephropathy prevention and treatment, but new modalities are needed. Summary: Recent advances in molecular biology and genetics will bring new insights to the mechanisms involved in diabetic nephropathy development. This will allow early identification of patients at risk of, or safe from, diabetic nephropathy and will hopefully lead to preventive strategies, based on the understanding of the pathophysiology of the disorder. Meanwhile, aggressive implementation of proven therapies to prevent (glycemic control) and slow (antihypertensive therapy, especially with renin-angiotensin system blockers) the progression of diabetic nephropathy are strongly recommended.

KW - Diabetic nephropathy

KW - Pathology

KW - Pathophysiology

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0037614775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037614775&partnerID=8YFLogxK

U2 - 10.1097/00041552-200305000-00008

DO - 10.1097/00041552-200305000-00008

M3 - Review article

C2 - 12698065

AN - SCOPUS:0037614775

VL - 12

SP - 273

EP - 282

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 3

ER -